ReviewAbdominal radiology (New York)2021
Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.
Review in Abdominal radiology (New York), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 66 citations in OpenAlex.
- Quantitative Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Radioembolization.Investigative radiology · 2026Trial
- Radiosensitization of intrahepatic cholangiocarcinoma and metastatic disease in the liver using microbubble cavitation: results from a phase 2 clinical trial.Cancer letters · 2025Trial
- Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial.Radiology · 2025Trial
- 3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation.European radiology · 2025Trial
- Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial.Radiology · 2023Trial
- Contrast-enhanced ultrasound LI-RADS nonradiation treatment response assessment: applications, challenges, and future directions.Abdominal radiology (New York) · 2026Review
- Umbilical vein recanalization identified on contrast-enhanced ultrasound in a patient with hepatocellular carcinoma during TACE assessment.Radiology case reports · 2026Article
- Site-Specific Native Antibody-Conjugated Microbubbles for Molecular Ultrasound Imaging of Hepatocellular Carcinoma.Molecular imaging and biology · 2026Article
- Review
- Irreversible electroporation ablation with bipolar electrodes: ultrasound findings of ablation zones.Radiology and oncology · 2026Article
- Spatiotemporal characterization of placental hypoxia and microvascular dysfunction in a preeclampsia rat model using photoacoustic and contrast-enhanced ultrasound.Quantitative imaging in medicine and surgery · 2026Article
- MEP-Net: a PIDNet-based model with median-enhanced spatial-channel attention for segmentation of hepatocellular carcinoma in CEUS images.BMC medical imaging · 2026Article
- Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation.Hepatology international · 2026Article
- Systematic evaluation and meta-analysis of the diagnostic accuracy of ultrasound contrast in predicting the efficacy of systemic therapy for advanced hepatocellular carcinoma.Translational cancer research · 2026Article
- Site-Specific Native Antibody-Conjugated Microbubbles for Molecular Ultrasound Imaging of Hepatocellular Carcinoma.Research square · 2026Article
- Dual-modality imaging with CEUS and MRI for early recurrence assessment in hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization.Frontiers in oncology · 2026Article
- The predictive value of preoperative ultrasound contrast parameters for early recurrence after transarterial chemoembolization for hepatocellular carcinoma.Frontiers in medicine · 2026Article
- Early screening for liver cancer must be performed.World journal of hepatology · 2025Review
- Clinical value of contrast-enhanced ultrasound in early diagnosis of hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a global problem constituting the second leading cause of cancer deaths worldwide, thereby necessitating an accurate and cost-effective solution for managing care. Ultrasound is well poised to address this need due to its low cost, portability, safety, and excellent temporal resolution. The role of ultrasound for HCC screening has been well established and supported by multiple international guidelines. Similarly, contrast-enhanced ultrasound (CEUS) can be used for the characterization of focal liver lesions in high-risk populations, and standardized criteria for CEUS have been established by the American College of Radiology Liver Imaging Reporting & Data System (LI-RADS). Following HCC identification, CEUS can also be highly beneficial in treatment planning, delivery, and monitoring HCC response to locoregional therapies. Specific advantages of CEUS include providing real-time treatment guidance and improved diagnostic performance for the detection of residual tumor viability or recurrence, thereby identifying patients in need of retreatment substantially earlier than contrast-enhanced CT and MRI. This review provides a primer on ultrasound and CEUS for the screening and characterization of HCC, with an emphasis on assessing tumor response to locoregional therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.